4.3299
Anteris Technologies Global Corp Aktie (AVR) Neueste Nachrichten
Anteris Technologies Global (AVR) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Should you wait for a breakout in Anteris Technologies Global Corp.July 2025 Earnings & Fast Entry and Exit Trade Plans - newser.com
Will Anteris Technologies Global Corp. continue its uptrendJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - newser.com
Using flow based indicators on Anteris Technologies Global Corp.July 2025 Short Interest & Long-Term Growth Plans - newser.com
Anteris Technologies Updates Capital Raising Timetable - MSN
Anteris Technologies Announces Cessation of Securities - The Globe and Mail
How strong is Anteris Technologies Global Corp. stock balance sheetLayoff News & Free Long-Term Investment Growth Plans - newser.com
Anteris Technologies Global Corp. stock momentum explainedQuarterly Earnings Report & Reliable Volume Spike Trade Alerts - newser.com
Detecting price anomalies in Anteris Technologies Global Corp. with AIJuly 2025 Reactions & Momentum Based Trading Ideas - newser.com
Using data models to predict Anteris Technologies Global Corp. stock movement2025 Volume Leaders & Verified Momentum Stock Watchlist - newser.com
Anteris Technologies: Strategic Advancements and FDA Approval Bolster Buy Rating - TipRanks
Anteris Technologies Secures FDA Approval for Global PARADIGM Trial - MSN
Will Anteris Technologies Global Corp. see short term momentum - newser.com
Anteris Technologies Receives FDA Approval for PARADIGM Trial - TipRanks
Anteris Technologies Global Corp FDA Approval for PARADIGM Trial - TradingView
[8-K] Anteris Technologies Global Corp. Reports Material Event | AVR SEC FilingForm 8-K - Stock Titan
What machine learning models say about Anteris Technologies Global Corp.2025 Institutional Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the 'PARADIGM Trial”) - The Manila Times
FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”) - Stock Titan
Anteris Technologies Initiates Global Trial for Innovative Heart Valve - MSN
Analyzing Anteris Technologies Global Corp. with multi timeframe chartsJuly 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Is it time to cut losses on Anteris Technologies Global Corp.2025 Year in Review & Expert Verified Movement Alerts - newser.com
Published on: 2025-11-03 02:48:19 - newser.com
Why Anteris Technologies Global Corp. stock is seen as undervalued - newser.com
Can Anteris Technologies Global Corp. hit a new high this monthQuarterly Trade Report & Safe Entry Zone Tips - newser.com
How rising interest rates impact Anteris Technologies Global Corp. stockWeekly Loss Report & Low Drawdown Investment Ideas - newser.com
Anteris Technologies Receives US FDA Approval for Transcatheter Heart Valve Trial; Shares Up 11% - MarketScreener
Will Anteris Technologies Global Corp. stock continue dividend increasesRecession Risk & Verified Chart Pattern Trade Signals - newser.com
Anteris Technologies Global Corp says FDA approves DurAVR THV global pivotal trial - MarketScreener
Is Anteris Technologies Global Corp. stock a safe buy before earningsGDP Growth & Weekly Market Pulse Updates - newser.com
What does recent volatility data suggest for Anteris Technologies Global Corp.CPI Data & Accurate Entry and Exit Point Alerts - newser.com
Anteris Technologies Global Corp. (AVR.AX) Analyst insights, Price targets and Recommendations - Yahoo! Finance Australia
Anteris Technologies Global Corp. (AVR) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Combining machine learning predictions for Anteris Technologies Global Corp.Earnings Recap Report & Fast Gaining Stock Reports - newser.com
Anteris Technologies Global Corp. (AVR) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Anteris Technologies Files Preliminary Proxy Statement for 2025 Annual Meeting - MSN
Anteris Technologies Advances Capital Raising Efforts to Strengthen Market Position - MSN
Weiss Ratings Reaffirms "Sell (D-)" Rating for Anteris Technologies Global (NASDAQ:AVR) - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):